By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

PharmaEngine, Inc. 

16F, 237 Sung-Chiang Road

Taipei  Taiwan  104  Republic of China
Phone: 886-2-2515-8228 Fax: 886-2-2515-7558


SEARCH JOBS


Industry
Pharmaceutical






Company News
Nanobiotix Receives U.S. $1 Million Milestone Payment From PharmaEngine, Inc. 6/1/2016 8:53:13 AM
PharmaEngine, Inc. Announces Initiation Of Global Pivotal Trial Of PEP503 (NBTXR3) In Soft Tissue Sarcoma In Asia Pacific Region 6/1/2016 6:43:29 AM
PharmaEngine, Inc. Announces Korean Ministry Of Food And Drug Safety Accepted The NDA Filing Of ONIVYDE For The Treatment Of Metastatic Pancreatic Cancer 5/11/2016 7:56:39 AM
PharmaEngine, Inc. Announces Taiwan FDA Granting The Product License Of ONIVYDE (Irinotecan Liposome Injection) For The Treatment Of Metastatic Pancreatic Cancer 3/7/2016 6:18:29 AM
PharmaEngine, Inc. Announces The Lancet Publication Of The ONIVYDE Phase 3 NAPOLI-1 Study 11/23/2015 6:26:11 AM
PharmaEngine, Inc. Announces Taiwan FDA Approval of ONIVYDE (irinotecan liposome injection) For The Treatment Of Metastatic Pancreatic Cancer 10/22/2015 8:39:43 AM
PharmaEngine, Inc. Release: MM-398 Receiving The Priority Review Designation By US FDA For New Drug Application And The Acceptance Of Market Authorization Application By EMA In Post-Gemcitabine Metastatic Pancreatic Cancer 6/26/2015 6:25:36 AM
PharmaEngine, Inc. Announces Filing New Drug Application (NDA) Of MM-398 (PEP02) To Taiwan FDA As A Treatment For Post-Gemcitabine Metastatic Pancreatic Cancer 6/1/2015 6:56:56 AM
PharmaEngine, Inc. Announces Filing By Baxter BioScience Corporation (BAX) Of Marketing Authorization Application Of MM-398 (PEP02) To The European Medicines Agency For Post-Gemcitabine Metastatic Pancreatic Cancer Patients 5/4/2015 9:02:45 AM
PharmaEngine, Inc. Announces Merrimack (MACK) Completed MM-398 (PEP02) New Drug Application Submission To U.S. FDA 4/28/2015 10:37:15 AM
123
//-->